[The joint use of prednisolone and phospholipid-containing hepatoprotectors in experimental chronic hepatitis].
In chronic CCl4-hepatitis in rats phospholipid-containing hepatoprotectors, essentiale and eplir differ in their influence on the therapeutic effect of prednisolone; essentiale does not change the antiproliferative effect of the glucocorticoid and weakens its membrane-stabilizing effect, eplir increases these therapeutic effects of prednisolone. Besides, eplir, in distinction from essentiale, reduces lipid accumulation in the liver and hypoproteinemia which are induced by prednisolone.
Vengerovskiĭ
A I
AI
Department of Pharmacology, Siberian Medical University, Tomsk, Russia.
Golovina
E L
EL
Kovalenko
M Iu
MIu
Chuchalin
V S
VS
Saprykina
E V
EV
Sosnina
N V
NV
Burkova
V N
VN
Saratikov
A S
AS
D000818:Animals; D002252:Carbon Tetrachloride Poisoning / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D002338:Carotenoids / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000627:therapeutic use*; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010743:Phospholipids / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D051381:Rats
D004338:Drug Combinations; D005938:Glucocorticoids; D010713:Phosphatidylcholines; D010743:Phospholipids; C064845:eplir; C011246:essential 303 forte; D002338:Carotenoids; D011239:Prednisolone